Mikrobiomik is a biopharmaceutical company founded for the research, development, production and commercialization of biologic medicines based on the human microbiome.
At Mikrobiomik we are developing a new generation of biologic medicines based on the human microbiome, focused on serious diseases, currently without therapeutic alternative such as non-alcoholic steatohepatitis.
Our first biologic medicine under investigation, MBK-01, aimed at treating intestinal infection caused by Clostridioides difficile, is in Phase III ongoing and is expected to be launched on the European market in the first half of 2024.
